Daniel J. Estes
Director/Board Member at Semnur Pharmaceuticals, Inc.
Profile
Daniel J.
Estes is currently a Director at Semnur Pharmaceuticals, Inc., Outpost Medicine, Inc., Cirius Therapeutics, Inc., Lengo Therapeutics, Inc., Inipharm, Inc., Sudo Biosciences, Inc., Radionetics Oncology, Inc., and Frazier Management LLC.
He previously served as an Independent Director at Sierra Oncology, Inc. and Arcutis Biotherapeutics, Inc. He also worked as a Consultant at McKinsey & Co., Inc. and as a Research Assistant at Stanford University and the University of Michigan.
Dr. Estes obtained his undergraduate degree from Stanford University in 2003 and his doctorate degree from the University of Michigan in 2008.
Daniel J. Estes active positions
| Companies | Position | Start |
|---|---|---|
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Private Equity Investor | 2011-03-31 |
Semnur Pharmaceuticals, Inc.
 Semnur Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Semnur Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm focuses on the clinical and commercial development of products such as SP-102: a non-opioid epidural steroid injectable potentially for the treatment of Lumbosacral radicular pain. The company was founded by Mahendra G. Shah in 2013 and is headquartered in Mountain View, CA. | Director/Board Member | - |
Outpost Medicine, Inc.
 Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Director/Board Member | 2016-03-14 |
Cirius Therapeutics, Inc.
 Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Director/Board Member | 2017-02-28 |
Lengo Therapeutics, Inc.
 Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Director/Board Member | - |
Inipharm, Inc.
 Inipharm, Inc. Pharmaceuticals: MajorHealth Technology Inipharm, Inc. provides health care services. The company was founded by Brian Farmer and Mike Gallatin in 2018 and is headquartered in Bellevue, WA. | Director/Board Member | - |
Sudo Biosciences, Inc.
 Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Director/Board Member | - |
Radionetics Oncology, Inc.
 Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Director/Board Member | - |
Former positions of Daniel J. Estes
| Companies | Position | End |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Director/Board Member | 2020-07-31 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Daniel J. Estes
| University of Michigan | Doctorate Degree |
| Stanford University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Health Technology |
| Private companies | 10 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Finance |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Semnur Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm focuses on the clinical and commercial development of products such as SP-102: a non-opioid epidural steroid injectable potentially for the treatment of Lumbosacral radicular pain. The company was founded by Mahendra G. Shah in 2013 and is headquartered in Mountain View, CA. | Health Technology |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Health Technology |
Lengo Therapeutics, Inc.
Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Health Technology |
Inipharm, Inc.
Inipharm, Inc. Pharmaceuticals: MajorHealth Technology Inipharm, Inc. provides health care services. The company was founded by Brian Farmer and Mike Gallatin in 2018 and is headquartered in Bellevue, WA. | Health Technology |
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Technology Services |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Health Technology |
- Stock Market
- Insiders
- Daniel J. Estes
